Table 3. In vivo antileukaemic effect of ssHHT.

Patient no.	Dose (mg m−2)	Blood blast clearance	Bone marrow D10	Blood/bm at the end of cytopaenia	Result of treatment
1	0.5	D8	94% blasts	Leukaemic	Blood blast clearance
2	0.5	No clearance	Not done	Leukaemic	No effect
3	0.5	Not evaluable	Not done	Leukaemic	No effect
4	3	D7	74% blasts	Leukaemic	Blood blast clearance
6	3	Not evaluable	63% blasts	Leukaemic	No effect
7	3	D4	Clearance	Death	Blood and bm clearance
8	5	D6	70% blasts	Leukaemic	Blood blast clearance
9	5	D11	Clearance	15% in bm	Blood and bm clearance
10	5	D7	Not done	Death	Blood blast clearance
11	5	Not evaluable	76% blasts	18% in bm	Reduction of bone marrow blasts
12	5	Not evaluable	25% blasts	Leukaemic	No effect
13	5	D3	Clearance	Aplastic at D36	Blood and bm clearance
14	5	D5	Clearance	4% in bm	CR (4 months)
15	5	D4	Not done	4% in bm	CR (3 months)
16	5	D6	41% blasts	42% in bm	Blood blast clearance
17	5	Not evaluable	12% blasts	5.5% in bm	Blood and bm clearance
18	5	D7	Clearance	7.5% in bm	Return to CMML (6 months)
19	5	D6	Not done	Aplastic at D38	Blood and bm clearance

CMML, chronic myelomonocytic leukaemia; CR, complete remission.